In medicine, the 2010s may be remember as a period of explosive growth of engineered therapeutics. This is driven primarily by better understanding of diseases

In medicine, the 2010s may be remember as a period of explosive growth of engineered therapeutics. This is driven primarily by better understanding of diseases (and their molecular targets) and also by an expanding reach of bio-engineering platforms. Monoclonal antibody approvals especially have accelerated briskly for inflammatory conditions (there are 13 or more for the skin condition psoriasis alone) and perhaps more famously redefined many cancer treatment regimens with checkpoint inhibitors. Chimeric antigen receptor T cell (CAR T cells) are (very) expensive ex vivo gene-edited cell-based treatments, and other platforms for gene editing with are nearing or entering trials. This trend does not appear to be decelerating or plateauing.